Fexinidazole

Fexinidazole (HOE 239) is an orally active, potent nitroimidazole antitrypanosomal agent. Fexinidazole shows trypanocidal activity against T. brucei subspecies and strains with IC50s of 0.7-3.3 μM (0.2-0.9 μg/ml) . Fexinidazol has the potential for human sleeping sickness (HAT) caused by infection with T. brucei[1].

Product Specifications

CAS Number

[59729-37-2]

Product Name Alternative

HOE 239

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Parasite

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Fexinidazole.html

Purity

99.92

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : < 0.1 mg/mL

Smiles

O=[N+](C1=CN=C(COC2=CC=C(SC)C=C2)N1C)[O-]

Molecular Formula

C12H13N3O3S

Molecular Weight

279.31

Precautions

H302, H315, H319, H335

References & Citations

[1]Kaiser M, et al. Antitrypanosomal activity of fexinidazole, a new oral nitroimidazole drug candidate for treatment of sleeping sickness. Antimicrob Agents Chemother. 2011 Dec;55 (12) :5602-8.